170 related articles for article (PubMed ID: 37669106)
21. Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations.
Cheng CD; Chen C; Wang L; Dong YF; Yang Y; Chen YN; Niu WX; Wang WC; Liu QS; Niu CS
Anal Cell Pathol (Amst); 2022; 2022():2376288. PubMed ID: 35757013
[TBL] [Abstract][Full Text] [Related]
22. Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.
Rangel-Pozzo A; Liu S; Wajnberg G; Wang X; Ouellette RJ; Hicks GG; Drachenberg D; Mai S
Cells; 2020 Aug; 9(8):. PubMed ID: 32784507
[TBL] [Abstract][Full Text] [Related]
23. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
[TBL] [Abstract][Full Text] [Related]
24. "Zooming in" on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing.
Khalafallah AM; Huq S; Jimenez AE; Serra R; Bettegowda C; Mukherjee D
Neurosurgery; 2021 Feb; 88(3):477-486. PubMed ID: 32674143
[TBL] [Abstract][Full Text] [Related]
25. Omics sciences and precision medicine in glioblastoma.
Micheletti C; Bonetti G; Madeo G; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Manganotti P; Caruso P; Bernini A; Fulcheri E; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):77-84. PubMed ID: 37994751
[TBL] [Abstract][Full Text] [Related]
26. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
Verdugo E; Puerto I; Medina MÁ
Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
[TBL] [Abstract][Full Text] [Related]
27. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
[TBL] [Abstract][Full Text] [Related]
28. The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study.
Garrett AM; Lastakchi S; McConville C
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32041307
[TBL] [Abstract][Full Text] [Related]
29. Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma.
Williams G; Llewelyn A; Thatcher R; Hardisty KM; Loddo M
PLoS One; 2022; 17(3):e0245817. PubMed ID: 35324914
[TBL] [Abstract][Full Text] [Related]
30. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC
J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619
[TBL] [Abstract][Full Text] [Related]
31. Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing.
Su S; Zou JJ; Zeng YY; Cen WC; Zhou W; Liu Y; Su DH; Zhang XL; Huang HY; Lei A; Huang ZH; Jin Y; Li L; Su N; Xie YL; Zhao ZG; Liu JX
Biomed Res Int; 2019; 2019():6096350. PubMed ID: 31781628
[TBL] [Abstract][Full Text] [Related]
32. Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
Davis B; Shen Y; Poon CC; Luchman HA; Stechishin OD; Pontifex CS; Wu W; Kelly JJ; Blough MD;
Neuro Oncol; 2016 Mar; 18(3):350-60. PubMed ID: 26245525
[TBL] [Abstract][Full Text] [Related]
33. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.
Lazaridis L; Schmidt T; Oster C; Blau T; Pierscianek D; Siveke JT; Bauer S; Schildhaus HU; Sure U; Keyvani K; Kleinschnitz C; Stuschke M; Herrmann K; Deuschl C; Scheffler B; Kebir S; Glas M
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3513-3526. PubMed ID: 35953681
[TBL] [Abstract][Full Text] [Related]
34. Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?
Panovska D; De Smet F
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955765
[TBL] [Abstract][Full Text] [Related]
35. Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations.
Pastorino F; Capasso M; Brignole C; Giglio S; Bensa V; Cantalupo S; Lasorsa VA; Tondo A; Mura R; Sementa AR; Garaventa A; Ponzoni M; Amoroso L
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232538
[TBL] [Abstract][Full Text] [Related]
36. Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method.
Kunkle B; Yoo C; Roy D
Neurotoxicology; 2013 Mar; 35():1-14. PubMed ID: 23261424
[TBL] [Abstract][Full Text] [Related]
37. Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes.
Chen Y; Gao Z; Wang B; Xu R
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):516. PubMed ID: 27557118
[TBL] [Abstract][Full Text] [Related]
38. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.
Mueller S; Jain P; Liang WS; Kilburn L; Kline C; Gupta N; Panditharatna E; Magge SN; Zhang B; Zhu Y; Crawford JR; Banerjee A; Nazemi K; Packer RJ; Petritsch CK; Truffaux N; Roos A; Nasser S; Phillips JJ; Solomon D; Molinaro A; Waanders AJ; Byron SA; Berens ME; Kuhn J; Nazarian J; Prados M; Resnick AC
Int J Cancer; 2019 Oct; 145(7):1889-1901. PubMed ID: 30861105
[TBL] [Abstract][Full Text] [Related]
39. Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma.
Jones DC; Scanteianu A; DiStefano M; Bouhaddou M; Birtwistle MR
PLoS One; 2018; 13(1):e0190664. PubMed ID: 29342193
[TBL] [Abstract][Full Text] [Related]
40. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
